Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW842166X · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving GW842166 | EXPERIMENTAL | Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive \[carbonyl-\^11C\]GW842166. |
| Name | Type | Description |
|---|---|---|
| GW842166X | DRUG | GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X. |
| [carbonyl-^11C]GW842166 | DRUG | \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution. |
Inclusion Criteria: * Male aged 50 to 80yrs inclusive at the screening visit. * subjects with negative HIV and hepatitis B and C test results within 3 months of study start. Exclusion Criteria: * A negative Allens test on arm to be used for arterial cannulation. * Any contraindications to MRI sca...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Ziltivekimab, Semaglutide |
GW842166X is an investigational small molecule developed by GSK plc for pain and inflammatory conditions. It is a cannabinoid receptor 2 (CNR2) agonist and has been studied in early-stage clinical research. It has not been approved for any indication and remains in clinical development.
GW842166X targets the cannabinoid receptor 2 (CNR2), where it acts as an agonist. CNR2 is a G protein-coupled receptor primarily expressed on immune cells and is studied for its role in pain and inflammatory signaling. This receptor is distinct from CNR1, the cannabinoid receptor most associated with psychoactive effects.
GW842166X is being developed by GSK plc, the British pharmaceutical company listed on the New York Stock Exchange under the ticker GSK. GSK originated the compound and sponsored its clinical research.
GW842166X is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval for any indication. Its only recorded trial was a Phase 1 study that has since been completed.
GW842166X has been studied in one completed Phase 1 trial, NCT00511524, titled an imaging study to investigate the distribution of GW842166X in the brain. The trial enrolled 6 healthy male volunteers aged 50 years and older in Sweden and was uncontrolled.